Computershare UK’s Post

Record pay to Britian's CEO in 2023 Mr. Pascal Soriot - CEO of AstraZeneca is the highest-paid British CEO with pay of 16.85 million pounds. Next is Mr. Erik Engstrom of information and analytics group RELX earning 13.64 million pounds. The bosses of Britain's biggest companies enjoyed record pay in 2023, with nine firms offering them packages of more than 10 million pounds ($12.75 million). The median pay for a FTSE-100 company CEO rose 2.2% to 4.19 million pounds last year.

Vitale companies making sustainable progress within their supply chains. Forward.

UK companies expand in Canada. This year's annual Top Companies in Canada list — a data-driven ranking of the 25 best workplaces to grow your career — is dominated by U.K. names, including pharma giant AstraZeneca as number 1, optical chain Specsavers, RSM International, EY and Deloitte. Why do so many British firms have a big or growing presence in the market? Canada offers a great talent pool, a "flexible approach" to relocating talent and hiring international workers, and allows foreign companies to easily set up teams serving clients across North America from the right time zone. - AstraZeneca is only doubling down going forward, having recently acquired Hamilton-based biopharmaceutical oncology company Fusion Pharmaceuticals for up to US$2.4 billion. - Specsavers recently opened its 100th store in Canada, just two years after entering the market.

AstraZeneca’s CEO pay proposals for its 11 April 2024 AGM face a shareholder revolt after both ISS And Glass Lewis have recommended a vote against. But given the size and indusrty of AstraZeneca, and its use of, and exposure to the global talent market, particularly the USA the proposal seems to be preventative of trouble ahead, rather than curative of a current pay malaise within the current package. Much medical thinking likes preventative in preference to curative solutions, and so this approach seems reasonable, but the big question remains - is the quantum and mix proposal judged in the round a good move? And all this in the context of the LSE “Big Tent” discussion on UK competitiveness in many dimensions, including that of executive compensation levels and governance. NEWSPOINT takes a closer look… https://lnkd.in/e285CibR #executiveremuneration #LSE #astrazeneca #bigtent #corpgro #corporategrowth

AstraZeneca’s CEO pay proposals for its 11 April 2024 AGM face a shareholder revolt after both ISS And Glass Lewis have recommended a vote against. But given the size and indusrty of AstraZeneca, and its use of, and exposure to the global talent market, particularly the USA the proposal seems to be preventative of trouble ahead, rather than curative of a current pay malaise within the current package. Much medical thinking likes preventative in preference to curative solutions, and so this approach seems reasonable, but the big question remains - is the quantum and mix proposal judged in the round a good move? And all this in the context of the LSE “Big Tent” discussion on UK competitiveness in many dimensions, including that of executive compensation levels and governance. NEWSPOINT takes a closer look… https://lnkd.in/e285CibR #executiveremuneration #LSE #astrazeneca #bigtent #corpgro #corporategrowth

As India marks its 78th year of independence, we at AstraZeneca draw inspiration from the nation's unwavering spirit of progress and resilience. We are dedicated to contributing to a healthier, independent India, ensuring that every citizen has access to world-class healthcare. By merging cutting-edge science, advanced data analytics, and innovative technologies, we are at the forefront of medical advancement. Our patient-centric approach ensures that every decision is guided by their needs, enabling them to live fuller lives. With a 45-year legacy of transforming healthcare, AstraZeneca India continues to focus on developing groundbreaking treatments aimed at improving patient outcomes, optimising healthcare systems, and protecting the environment. Together, let's build a healthier, more resilient India with AstraZeneca's commitment to science-based innovation and patient well-being. #IndependenceDay #15August #78IndependenceDay

100 years in India & it’s been a long eventful run for GSK. Generations have grown up on Farex (it has long changed hands) and its amoxy-clav combo, which made its debut in the 80s, still leads the brands league table in India. GSK India chief Bhushan Akshikar reflects on the company’s history, what’s kept it relevant, some bold bets made along the way, how it has contemporized brands, efforts on new category creation, the Amazon like model for #vaccine ordering and much more. “There are no old or new brands, only old minds. We look at every single brand/asset, as a trust mark/a signature of quality,” Akshikar declared. What about the reversal in rankings from when MNCs ruled the roost pre 1970 to now where Indian companies lead the rankings? He has an interesting take on that too & the new temples of industry. Plus, GSK dominated the market for > than 75 yrs, he underlines. PS: Still remember some of the GSK AGMs of yore & the doyens at the helm over the yrs – H Dharajgir, V Thyagarajan, HR Khusrokhan, S Kalyanasundaram .........& more recently A Vaidheesh, S Venkatesh. Citeline Commercial

On the 25th anniversary of the merger between Astra and Zeneca, AstraZeneca Türkiye shared a comprehensive report evaluating AstraZeneca's economic and social impacts in Türkiye. According to the "Impact of AstraZeneca on Türkiye" Report, the actual value of the company's total GDP impact on Türkiye over 25 years, considering both indirect and induced effects, totals 195 billion TL, supporting an additional 11 jobs in the economy for every job provided. Serkan BARIS, Country President of AstraZeneca Türkiye, who underlined their perseverance in improving health outcomes globally and in Türkiye, said, "Türkiye is a crucial country within our global and regional structure. We are one of the largest international pharmaceutical companies in Türkiye. With over 500 employees, we provide services based on our treatment areas and have a presence in 29 geographical regions. We are not just a part of the healthcare ecosystem; we are a solution partner within this ecosystem. While enhancing health outcomes with our potent medications, we actively participate with stakeholders in developing healthcare service processes." Dr. Deniz Erturk Erem, the Medical Director of AstraZeneca Türkiye, emphasized their belief that a healthier society and a sustainable healthcare system can be achieved through stakeholder collaboration. She said, "We support many initiatives in our country's healthcare ecosystem that endorse innovative solutions, including universities and medical associations." She added, "We collaborate with many centers across Türkiye to generate and support the production of real-life data to contribute to fields such as heart failure, chronic kidney disease, asthma, lung cancer, and more." Erdal Kiraz, the Director of Corporate Affairs at AstraZeneca Türkiye, highlighted that their efforts extend beyond drug development and healthcare service provision to addressing societal issues. He stated, "AstraZeneca's work in the social impact domain includes focusing on areas such as improving access to healthcare, enhancing education, promoting health literacy, addressing societal needs in disasters and other emergencies, promoting diversity and inclusivity, and managing environmental impacts. Additionally, we work to facilitate access to primary healthcare services, raise awareness about public health, and expand activities such as screening." #socialimpact #economicimpact #scientificimpact  #AstraZenecaTürkiye #25thAnniversary #AstraZeneca #WhatScienceCanDo

In a quiet week, the UK press were kept busy with various rumours about the Spring Budget. We had one contact that suggested this Budget may be the first part of a fiscal trilogy due to the lack of financial wriggle room now. Elsewhere US GBP numbers were good, and the Yen strengthened (which has been a very rare occurrence!). The political football that is the UK housebuilding sector also came under pressure due to a review by the CMA – competition and markets authority. A UK stock market bellwether, Reckitt Benckiser disappointed analysts (and holders) and Direct Line was the latest company to be approached for takeover. Hunting and IMI had decent prints and Frasers Group went shopping! Over the pond Warren Buffett made a tribute to Charlie Munger in Berkshire’s quarterly report. Snowflake’s share price melted as Universal Music hit the right note! (sorry). At the beginning of February, we highlighted some car manufacturers putting the brake on their EV expansion. This week we had a leak from Apple that their “Project Titan” EV project had been parked and Mercedes and Aston Martin both paused their new divisions. Is it simply a battle between Tesla and the Chinese manufacturers, or maybe Frasers (see above) are correct and EVs should stick to Scalextric? The US stock market has the “Magnificent 7.” In Europe, they have the “Granolas” a term coined by Goldman Sachs to describe 11 ascendant European companies that have lifted European markets to a record high. They have contributed half of the Stoxx Europe 600 increase over the last year! #TWTWTW #ThatWasTheWeekThatWas #vermeerpartners #theartofinvestment #granolas #mag7 #ev

Organisational transformation to be future ready is a complex process. It requires bold steps where heritage has to be critically viewed & at times divested in pursuit of future goals. Therapies are evolving from symptomatic cures to fundamental cures. Sharp targeted therapies which deliver value to the patient is more in vogue. Focus on immunotherapy, rare blood disorders vaccines are future proofing combined with massive capability building of AI. These are transformative times @ sanofi.